Étiquette : cannabis use disorders

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017, Hongying Dai & Kimber P. Richter, 2019

A National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017 Hongying Dai, Kimber P. Richter JAMA Network Open, 2019, 2, (9), e1911936. doi:10.1001/jamanetworkopen.2019.11936   Abstract IMPORTANCE : The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES : To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by sociodemographic group, and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN, SETTING, AND PARTICIPANTS : This survey study used a probability [...]

Lire la suite

Adolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus, Grace Blest‐Hopley et al., 2019

Adolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus Grace Blest‐Hopley | Aisling O'Neill | Robin Wilson | Vincent Giampietro | David Lythgoe | Alice Egerton | Sagnik Bhattacharyya Addiction Biology, 2019, e12827, 1-11. DOI: 10.1111/adb.12827   Abstract Cannabis use has been associated with adverse mental health outcomes, the neurochemical underpinnings of which are poorly understood. Although preclinical evidence suggests glutamatergic dysfunction following cannabis exposure in several brain regions including the hippocampus, evidence from human studies have been inconsistent. We investigated the effect of persistent cannabis use on the brain levels of N‐acetyl aspartate (NAA) and myo-inositol, [...]

Lire la suite

Heavy cannabis use, dependence and the brain : a clinical perspective, Emese Kroon et al., 2019

Heavy cannabis use, dependence and the brain : a clinical perspective Emese Kroon, Lauren Kuhns, Eva Hoch & Janna Cousijn Addictions, 2019, 1-12. doi : 10.1111/add.14776   ABSTRACT Aims : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, cannabis use disorder (CUD) and the brain. Methods : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. Results : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]

Lire la suite

Long-term Heavy Cannabis Use : implications for health education, Niall COGGANS et al., 2004

Long-term Heavy Cannabis Use : implications for health education Niall COGGANS, Phil DALGARNO, Lindsay JOHNSON & David SHEWAN Drugs : education, prevention and policy, 2004, Vol. 11, No. 4, 299–313   ABSTRACT There is growing evidence that cannabis can have negative effects on health. While the ongoing debate about the nature and duration of these effects recognizes mild cognitive impairment, the evidence for irreversibility of cognitive impairment and causal links with psychiatric illness is not conclusive. There is undoubtedly potential for impairment of respiratory functioning, but that will depend on lifetime load and in most cases is confounded with tobacco smoking. There is a [...]

Lire la suite

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study, Nadav Shalita et al., 2019

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]

Lire la suite

Cannabis use, dependence and withdrawal in indigenous male inmates, Bernadette Rogerson et al., 2014

Cannabis use, dependence and withdrawal in indigenous male inmates Bernadette Rogerson, Susan P. Jacups, and Nerina Caltabiano Journal of  Substance Use, 2014, 1–7 DOI: 10.3109/14659891.2014.950702 ISSN: 1465-9891 (print), 1475-9942 (electronic) Abstract Background : No studies have investigated cannabis withdrawal in indigenous or incarcerated populations, and there is currently no standard treatment for cannabis withdrawal in Australian prisons. Aims : This cross sectional survey examines cannabis use, dependence and involuntary (abrupt cessation) withdrawal in incarcerated indigenous males for the purpose of improving clinical management. Methods : 101 consenting inmates (18–40 years) from an Australian correction centre were interviewed. Demographic characteristics, lifetime cannabis use (LCU), severity of dependence, cannabis withdrawal [...]

Lire la suite

Heavy Cannabis Use, Dependence and the Brain : A Clinical Perspective, KROON E. et al., 2019

Heavy Cannabis Use, Dependence and the Brain: A Clinical Perspective KROON E., KUHNS L., HOCH E., COUSIJN J. Addictions,  2019 Aug 13. doi: 10.1111/add.14776. PMID: 31408248 Abstract AIMS : To summarize and evaluate our knowledge of the relationship between heavy cannabis use, Cannabis Use Disorder (CUD), and the brain. METHODS : Narrative review of relevant literature identified through existing systematic reviews, meta-analyses and a PubMed search. Epidemiology, clinical representations, potential causal mechanisms, assessments, treatment and prognosis are discussed. RESULTS : Although causality is unclear, heavy and dependent cannabis use is consistently associated with a high prevalence of comorbid psychiatric disorders and learning and memory impairments that seem [...]

Lire la suite

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies, Matthew E. Sloan et al., 2018

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z   Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]

Lire la suite

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, Albert Batalla et al., 2019

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]

Lire la suite

Cannabidiol and Canabis Use Disorder, María S. García-Gutiérrez et al., 2018

Cannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]

Lire la suite